EA017668B1 - Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов - Google Patents

Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов Download PDF

Info

Publication number
EA017668B1
EA017668B1 EA201070762A EA201070762A EA017668B1 EA 017668 B1 EA017668 B1 EA 017668B1 EA 201070762 A EA201070762 A EA 201070762A EA 201070762 A EA201070762 A EA 201070762A EA 017668 B1 EA017668 B1 EA 017668B1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
mol
formula
hours
dibenzo
Prior art date
Application number
EA201070762A
Other languages
English (en)
Russian (ru)
Other versions
EA201070762A1 (ru
Inventor
Константинос Гавардинас
Прабхакар Кондаджи Джадхав
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA017668(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201070762A1 publication Critical patent/EA201070762A1/ru
Publication of EA017668B1 publication Critical patent/EA017668B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
EA201070762A 2007-12-19 2008-12-09 Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов EA017668B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19
PCT/US2008/085997 WO2009085584A1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Publications (2)

Publication Number Publication Date
EA201070762A1 EA201070762A1 (ru) 2010-12-30
EA017668B1 true EA017668B1 (ru) 2013-02-28

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070762A EA017668B1 (ru) 2007-12-19 2008-12-09 Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов

Country Status (33)

Country Link
US (1) US7994164B2 (enExample)
EP (2) EP2537845B1 (enExample)
JP (1) JP5562866B2 (enExample)
KR (1) KR101254382B1 (enExample)
CN (1) CN101903377B (enExample)
AR (1) AR069554A1 (enExample)
AU (1) AU2008343524B2 (enExample)
BR (1) BRPI0820805A2 (enExample)
CA (1) CA2710409C (enExample)
CL (1) CL2008003600A1 (enExample)
CO (1) CO6300953A2 (enExample)
DK (1) DK2235007T3 (enExample)
DO (1) DOP2010000185A (enExample)
EA (1) EA017668B1 (enExample)
EC (2) ECSP10010266A (enExample)
ES (2) ES2459318T3 (enExample)
GT (1) GT201000179A (enExample)
HR (1) HRP20120916T1 (enExample)
IL (1) IL206353A (enExample)
MA (1) MA31910B1 (enExample)
MX (1) MX2010006911A (enExample)
MY (1) MY150474A (enExample)
NZ (1) NZ586300A (enExample)
PE (1) PE20091057A1 (enExample)
PL (1) PL2235007T3 (enExample)
PT (1) PT2235007E (enExample)
RS (1) RS52594B (enExample)
SI (1) SI2235007T1 (enExample)
TN (1) TN2010000292A1 (enExample)
TW (1) TWI431010B (enExample)
UA (1) UA100131C2 (enExample)
WO (1) WO2009085584A1 (enExample)
ZA (1) ZA201004257B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
WO2010104721A1 (en) * 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
EP2977084B1 (en) 2010-05-10 2017-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
WO2011157798A1 (en) 2010-06-16 2011-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for stimulating reepithelialisation during wound healing
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
NZ712949A (en) 2013-05-02 2017-04-28 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
SI3160948T1 (sl) 2014-06-30 2020-06-30 Astrazeneca Ab Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoida
NZ730759A (en) * 2014-11-21 2018-10-26 Lilly Co Eli 1,2-benzothiazole compounds for the treatment of kidney disorders
EP3362095B1 (en) 2015-10-13 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
ES2973248T3 (es) 2016-07-26 2024-06-19 Inst Nat Sante Rech Med Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis
MA45202B1 (fr) * 2016-09-24 2022-04-29 Kbp Biosciences Co Ltd Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation
WO2021180818A1 (en) 2020-03-11 2021-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345747A2 (en) * 1988-06-09 1989-12-13 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) * 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
FR2603713B1 (fr) * 1986-09-10 1992-07-24 Canon Kk Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
AR014195A1 (es) 1997-12-29 2001-02-07 Ortho Mcneil Pharm Inc Compuestos de trifenilpropanamida utiles para el tratamiento de procesos inflamatorios, composiciones anti-inflamatorias que los comprenden, ymetodos para prepararlos
JP2002541144A (ja) 1999-01-26 2002-12-03 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 医薬的に活性のある化合物及びその使用方法
PL403800A1 (pl) * 2001-11-21 2013-08-19 Millennium Pharmaceuticals, Inc. Kompozycja farmaceutyczna
WO2005066153A1 (en) 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
CN1918151A (zh) 2003-12-19 2007-02-21 伊莱利利公司 三环甾类激素核受体调节剂
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2008508314A (ja) 2004-07-28 2008-03-21 アイアールエム・リミテッド・ライアビリティ・カンパニー ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物
TWI400239B (zh) 2004-11-10 2013-07-01 Incyte Corp 內醯胺化合物及其作為醫藥品之用途
HRP20120078T1 (hr) 2006-10-31 2012-02-29 Pfizer Products Inc. Pirazolinski spojevi kao antagonisti mineralokortikoidnih receptora
US20100120736A1 (en) 2007-03-29 2010-05-13 N.V. Organon Mineralocorticoid Receptor Antagonists
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
US20100292233A1 (en) 2008-01-25 2010-11-18 Arena Pharmaceuticals, Inc. Dihydro-1h-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives which act as s1p1 agonists
WO2010104721A1 (en) 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345747A2 (en) * 1988-06-09 1989-12-13 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators

Also Published As

Publication number Publication date
IL206353A (en) 2014-06-30
EP2537845A1 (en) 2012-12-26
US7994164B2 (en) 2011-08-09
UA100131C2 (uk) 2012-11-26
EP2537845B1 (en) 2014-03-19
TWI431010B (zh) 2014-03-21
MA31910B1 (fr) 2010-12-01
ES2459318T3 (es) 2014-05-09
CA2710409A1 (en) 2009-07-09
JP2011507868A (ja) 2011-03-10
WO2009085584A1 (en) 2009-07-09
DK2235007T3 (da) 2012-12-17
TN2010000292A1 (en) 2011-11-11
IL206353A0 (en) 2010-12-30
RS52594B (sr) 2013-04-30
ECSP12012048A (es) 2012-08-31
GT201000179A (es) 2012-04-16
EP2235007A1 (en) 2010-10-06
PT2235007E (pt) 2013-01-22
DOP2010000185A (es) 2010-09-15
EP2235007B1 (en) 2012-10-31
AR069554A1 (es) 2010-02-03
AU2008343524A1 (en) 2009-07-09
EA201070762A1 (ru) 2010-12-30
MX2010006911A (es) 2010-10-05
CA2710409C (en) 2012-11-06
US20090163472A1 (en) 2009-06-25
KR20100082866A (ko) 2010-07-20
AU2008343524B2 (en) 2012-03-08
MY150474A (en) 2014-01-30
SI2235007T1 (sl) 2013-01-31
HRP20120916T1 (hr) 2012-12-31
ZA201004257B (en) 2011-11-30
KR101254382B1 (ko) 2013-04-15
ECSP10010266A (es) 2010-07-30
HK1144284A1 (en) 2011-02-11
NZ586300A (en) 2012-06-29
ES2396605T3 (es) 2013-02-22
CO6300953A2 (es) 2011-07-21
JP5562866B2 (ja) 2014-07-30
BRPI0820805A2 (pt) 2015-06-16
CN101903377B (zh) 2014-07-09
TW200930721A (en) 2009-07-16
CL2008003600A1 (es) 2010-02-19
PE20091057A1 (es) 2009-07-20
PL2235007T3 (pl) 2013-03-29
CN101903377A (zh) 2010-12-01

Similar Documents

Publication Publication Date Title
EA017668B1 (ru) Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов
AU2014242908B2 (en) Novel N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
JP6908536B2 (ja) ムスカリンｍ２受容体の正のアロステリックモジュレーター
RS59445B1 (sr) Derivat 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izohinolina koristan u tretmanu raka
BR112020026653A2 (pt) Compostos heterocíclicos como inibidores de trk
TW202400608A (zh) 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
EA029311B1 (ru) Hантагонисты, имеющие феноксипиперидиновое ядро в структуре, и их применение для лечения и/или профилактики состояний, опосредуемых hрецепторами
CN109689656B (zh) 7-取代的1-芳基二氮杂萘-3-羧酰胺及其用途
TW202417458A (zh) 調節her2的化合物及方法
EP4647433A1 (en) Shp2 inhibitor and uses thereof
US20250177539A1 (en) Er degraders and uses thereof
HK1144284B (en) 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists
WO2025122809A1 (en) M4 positive allosteric modulators
TW202430523A (zh) pan-KRAS降解劑及其製備方法與應用
TW202540107A (zh) Ｍ４陽性變構調節劑

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KG MD TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ TJ RU